PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.09%
Cash & equivalents declining -9.09% while Biotechnology shows -10.48% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Near the Biotechnology median of -8.42% for total liquid asset growth. Charlie Munger would check if this is standard for the industry cycle.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.56%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-10.41%
1.25-1.5x the Biotechnology median of -7.84%. Mohnish Pabrai would examine if this advantage is strategic or idle cash buildup.
-5.27%
PP&E growth 1.25-1.5x the Biotechnology median of -3.67%. Mohnish Pabrai might see an above-average capacity build if well-justified by demand.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.98%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
≥ 1.5x the Biotechnology median of -1.91%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
≥ 1.5x the Biotechnology median of -6.59%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-5.64%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
1.56%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-5.23%
Below half Biotechnology median of 3.07%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
Below half Biotechnology median of -1.65%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
Below half Biotechnology median of 0.34%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
0.75-0.9x Biotechnology median of -4.90%. John Neff wonders if the firm lags peers in reinvested profits.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.89%
≥ 1.5x Biotechnology median of -9.05%. Joel Greenblatt sees stronger equity growth vs. peers.
-10.20%
≥ 1.5x Biotechnology median of -6.57%. Joel Greenblatt sees more aggressive expansions than peers.
0.98%
≥ 1.5x Biotechnology median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-5.39%
Above 1.5x Biotechnology median of -1.19%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
9.19%
Near Biotechnology median 11.11%. Charlie Munger sees typical yoy changes in net debt among the sector.